Immune responses to microbial glycolipids that cross-react to neural epitopes may trigger the Guillain-Barré syndrome (GBS). CD1 molecules are involved in antigen presentation of glycolipids and variation in CD1 genes was recently reported to confer susceptibility to develop GBS. This hypothesis was tested by comparing single nucleotide polymorphisms (SNPs) of CD1A and CD1E in 312 well defined GBS patients and 212 healthy controls. SNPs in CD1A and CD1E were not associated with GBS susceptibility, specific clinical subgroups, anti-ganglioside antibodies, antecedent infections and prognosis. Based on this study, CD1 polymorphisms are not a susceptibility or disease modifying factor in GBS.

, , , ,,
Journal of Neuroimmunology
Erasmus MC: University Medical Center Rotterdam

Kuijf, M., Geleijns, K., Ennaji, N., van Rijs, W., van Doorn, P., & Jacobs, B. (2008). Susceptibility to Guillain-Barré syndrome is not associated with CD1A and CD1E gene polymorphisms. Journal of Neuroimmunology, 205(1-2), 110–112. doi:10.1016/j.jneuroim.2008.08.013